3,3',5'-Triiodo-L-thyronine | 70-39-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3,3',5'-Triiodo-L-thyronine
• 英文别名: 2-Azaniumyl-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3-iodophenyl]propanoate
• CAS: 70-39-3
• 化学式: C₁₅H₁₂I₃NO₄
• 分子量: 650.978
• InChiKey: HZCBWYNLGPIQRK-UHFFFAOYSA-N

物化性质

• 沸点：
  534.6±50.0 °C(Predicted)
• 密度：
  2.387±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  92.8
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 氨 、 碘 作用下， 生成 3,3',5'-Triiodo-L-thyronine
  参考文献：
  名称：

  Roche et al., Bulletin de la Societe Chimique de France, 1957, p. 464,465

  摘要：

  DOI：

文献信息

• BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS
  申请人：QUADRIGA BIOSCIENCES, INC.

  公开号：US20150218086A1

  公开（公告）日：2015-08-06

  β-Substituted β-amino acids, β-substituted β-amino acid derivatives, and β-substituted β-amino acid analogs and (bio)isosteres and their use as chemotherapeutic agents are disclosed. The β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs and (bio)isosteres are selective LAT1/4F2hc substrates and exhibit rapid uptake and retention in tumors expressing the LAT1/4F2hc transporter. Methods of synthesizing the β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs and methods of using the compounds for treating cancer are also disclosed. The β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs exhibit selective uptake in tumor cells expressing the LAT1/4F2hc transporter and accumulate in cancerous cells when administered to a subject in vivo. The β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs and (bio)isosteres exhibit cytotoxicity toward several tumor types.

  β-取代β-氨基酸，β-取代β-氨基酸衍生物，β-取代β-氨基酸类似物和（生物）同位素及其作为化疗药物的用途被披露。β-取代β-氨基酸衍生物和β-取代β-氨基酸类似物和（生物）同位素是选择性LAT1/4F2hc底物，并在表达LAT1/4F2hc转运蛋白的肿瘤中表现出快速摄取和保留。还披露了合成β-取代β-氨基酸衍生物和β-取代β-氨基酸类似物的方法以及使用这些化合物治疗癌症的方法。β-取代β-氨基酸衍生物和β-取代β-氨基酸类似物在表达LAT1/4F2hc转运蛋白的肿瘤细胞中表现出选择性摄取，并在体内给予受试者后在癌细胞中积累。β-取代β-氨基酸衍生物和β-取代β-氨基酸类似物和（生物）同位素对几种肿瘤类型表现出细胞毒性。
• BETA-SUBSTITUTED GAMMA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS
  申请人：QUADRIGA BIOSCIENCES, INC.

  公开号：US20150218085A1

  公开（公告）日：2015-08-06

  β-Substituted γ-amino acids, β-substituted γ-amino acid derivatives, and β-substituted γ-amino acid analogs and (bio)isosteres and their use as chemotherapeutic agents are disclosed. The β-substituted γ-amino acid derivatives and β-substituted γ-amino acid analogs and (bio)isosteres are selective LAT1/4F2hc substrates, capable of passing through the blood-brain barrier, and exhibit rapid uptake and retention in tumors expressing the LAT1/4F2hc transporter. Methods of synthesizing the β-substituted γ-amino acid derivatives and β-substituted γ-amino acid analogs and (bio)isosteres and methods of using the compounds for treating tumors are also disclosed. The β-substituted γ-amino acid derivatives and β-substituted γ-amino acid analogs and (bio)isosteres exhibit an improved selectivity toward tumor cells expressing the LAT1/4F2hc transporter and accumulate in cancerous cells when administered to a subject in vivo. The β-substituted γ-amino acid derivatives and β-substituted γ-amino acid analogs and (bio)isosteres exhibit an increased efficacy on a variety of tumor types.

  β-取代的γ-氨基酸，β-取代的γ-氨基酸衍生物，以及β-取代的γ-氨基酸类似物和（生物）同位素及其作为化疗药物的用途被披露。这些β-取代的γ-氨基酸衍生物和β-取代的γ-氨基酸类似物和（生物）同位素是选择性LAT1/4F2hc底物，能够穿过血脑屏障，并在表达LAT1/4F2hc转运蛋白的肿瘤中表现出快速摄取和保留。还披露了合成β-取代的γ-氨基酸衍生物和β-取代的γ-氨基酸类似物和（生物）同位素的方法以及使用这些化合物治疗肿瘤的方法。这些β-取代的γ-氨基酸衍生物和β-取代的γ-氨基酸类似物和（生物）同位素表现出对表达LAT1/4F2hc转运蛋白的肿瘤细胞的改进选择性，并在体内给予受试者时在癌细胞中积累。这些β-取代的γ-氨基酸衍生物和β-取代的γ-氨基酸类似物和（生物）同位素在多种肿瘤类型上表现出增加的疗效。
• [EN] TYPE III DEIODINASE INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE LA DÉSIODINASE DE TYPE III ET LEURS UTILISATIONS
  申请人：HADASIT MED RES SERVICE

  公开号：WO2015140792A1

  公开（公告）日：2015-09-24

  The present invention relates to compounds that inhibit the activity of Type III deiodinase (DIO3). The present invention further relates to methods for treating or preventing depression, depression associated with other psychiatric or general medical diseases or conditions, condition amenable to treatment with known anti-depressants and cancer, particularly by using the compounds of the invention.

  本发明涉及抑制第三型去碘酶（DIO3）活性的化合物。本发明还涉及治疗或预防抑郁症、与其他精神疾病或一般医学疾病相关的抑郁症、适合使用已知抗抑郁药物治疗的疾病或状况，以及癌症的方法，特别是通过使用本发明的化合物。
• Novel Phosphinic Acid-Containing Thyromimetics
  申请人：Erion Mark D.

  公开号：US20090028925A1

  公开（公告）日：2009-01-29

  The present invention relates to compounds of phosphonic acid-containing T3 mimetics and monoesters thereof, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndrome x and diabetes.

  本发明涉及含有磷酸基T3拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟
• Halogenated Phenols for Diagnostics, Antioxidant Protection and Drug Delivery
  申请人：Latham Keith R.

  公开号：US20180117164A1

  公开（公告）日：2018-05-03

  The present invention provides compositions and methods for the targeted delivery, release and/or formation of a drug compound at a target site(s) within the body of an individual, such as a diseased and/or inflamed tissue in the body of the individual. These compositions may comprise a halogenated phenol ring cleavably linked to a core structure of a drug compound. Due to the variety of substituents that may be utilized in forming the different types of linkages, numerous examples of drug compounds linked to a halogenated phenol ring are proposed. The present invention further provides compositions comprising halogenated phenol starting compounds that do not undergo cleavage during a dehalogenation reaction to form a drug compound in a targeted tissue when administered to an individual. Methods of administering these non-cleaving compounds are further provided.

  本发明提供了用于在个体体内的目标部位（如个体体内的患病和/或发炎组织）定向传递、释放和/或形成药物化合物的组合物和方法。这些组合物可能包括可被切断连接到药物化合物的核结构的卤代酚环。由于在形成不同类型的连接时可以利用的取代基的多样性，提出了与卤代酚环连接的药物化合物的众多示例。本发明还提供了包含卤代酚起始化合物的组合物，当向个体施用时，在靶向组织中不会在去卤反应期间发生切断以形成药物化合物。进一步提供了施用这些非切断化合物的方法。